Cooperative Agreement U01CA287036
Award Date
7/23/24
Completion Date
6/30/29
Dollars Obligated
$3M
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Cooperative Agreement
Place of Performance
Los Angeles, CA 90033, USA
Similar Awards
This Project Grant award of $704,882, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to define the genetic basis of prostate cancer risk in African American families. The key objectives are to: Enroll additional eligible first- and second-degree affected and unaffected family members from the existing RESPOND cohort to study genetic factors contributing to familial prostate cancer risk in African American...
The National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $613,220 project grant to the University of Southern California (USC) to investigate the contribution of germline copy number variations (CNVs) to the susceptibility of aggressive prostate cancer in men of African and European ancestry. The 5-year project, starting February 1, 2025, will combine imputation and sequencing-based approaches to comprehensively assess CNVs...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will support research conducted by Thomas Jefferson University to investigate genomic factors contributing to racial disparities in metastatic prostate cancer outcomes. The key products or services to be delivered under this $156,000 award include whole-exome sequencing of circulating tumor cells (CTCs) from paired Black and White patients with metastatic...
This federal Project Grant award of $334,233, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, will support a comprehensive research study examining disparities in novel cancer therapies, the joint effects of cancer treatment and comorbidities, and multi-level contributors to cancer survival outcomes. The University of South Carolina, the prime awardee, will conduct innovative data linkages between the state cancer registry,...
The National Cancer Institute (NCI) awarded a $287,300 Project Grant (CFDA 93.398 Cancer Research Manpower) to the University of California, Los Angeles (UCLA) to conduct research aimed at improving prostate cancer risk stratification and clinical management. The key objectives are to investigate whether DNA damage repair gene variants, prostate cancer polygenic risk, and genetic ancestry can help predict: 1) progression from active surveillance, and 2) biochemical relapse after therapy. The...
This Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Emory University provides $659,498 in funding to investigate racial disparities in the mechanisms of prostate cancer metastasis. The research aims to analyze differential pathway activity, particularly related to the FGFR3 signaling and oxidative phosphorylation (OXPHOS) pathways, and their impact on metastasis in African American men. The project will leverage in vitro and in vivo models, as...
This $1,050,000 Cooperative Agreement award, issued by the National Center for Chronic Disease Prevention and Health Promotion, is funded under the Centers for Research and Demonstration for Health Promotion and Disease Prevention (CFDA 93.135) program. The award, with a performance period from September 30, 2024 to September 29, 2027, supports research led by the University of California, San Francisco (UCSF) on patient perspectives regarding relabeling and pathology reporting for Grade Group 1...
The National Cancer Institute (NCI) awarded a 5-year, $162,160 Project Grant (CFDA 93.398 - Cancer Research Manpower) to The Ohio State University to improve the assessment of patient-reported outcomes (PROs) among Black/African-American cancer patients. The research will involve qualitative interviews with Black cancer patients and their providers to understand barriers and facilitators to completing PROs and social determinants of health (SDH) measures. This knowledge will inform the...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $577,529 to Health Research, Inc. to investigate the relationship between accelerated ribosomal DNA (rDNA) methylation age and early-onset prostate cancer in African American patients. The main objectives are to: 1) determine if African American prostate cancer patients exhibit higher rDNA methylation age at diagnosis compared to age-matched...
This federal Project Grant award of $1,839,317.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Illinois. The grant aims to evaluate the interrelated roles of environmental exposures and multi-omic factors on high-risk prostate cancer among men of African ancestry. Key components include: Establishing a translational study site at the University of Calabar Teaching Hospital in Nigeria to recruit 120...